Compare Gilead Sciences, Inc. (GILD) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MSCI China ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while iShares MSCI China ETF trades at $52.8 (market cap $6.00B). The key difference: Gilead Sciences, Inc. is far larger — about 30.3× iShares MSCI China ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares MSCI China ETF for 63 Days on average.
| GILD | MCHI | |
|---|---|---|
Market Cap | $182.09B | $6.00B |
Volume | 4,960,247 | 1,917,899 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $65.59 |
52-Week Low | $116.74 | $50.48 |
Typical Hold Time | 111 Days | 63 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
MCHI trades at $51.64, down 1.11% with a bearish technical signal from moving averages and oscillators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and trade tensions, though corporate profits surged 26% in Q2 2026. Support levels cluster around $51-52 with resistance at $52, indicating consolidation near current levels amid mixed market sentiment.
The outlook remains cautious due to China's macroeconomic pressures and global trade friction, though historical discount to US indices presents potential value. Key risks include export restrictions, protectionism threats, and domestic consumption weakness. Institutional activity shows mixed positioning with recent acquisitions offset by reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
